Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy
出版年份 2017 全文链接
标题
Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy
作者
关键词
-
出版物
Science Advances
Volume 3, Issue 5, Pages e1602133
出版商
American Association for the Advancement of Science (AAAS)
发表日期
2017-05-18
DOI
10.1126/sciadv.1602133
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
- (2017) Tomasz M. Beer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma.
- (2017) J. D. Wolchok et al. JOURNAL OF CLINICAL ONCOLOGY
- Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer Subjects
- (2016) Nadeem Sheikh et al. CANCER RESEARCH
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Prospects for the use of ipilimumab in treating advanced prostate cancer
- (2016) Xiao X. Wei et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Immune checkpoint therapy for non-small-cell lung cancer: an update
- (2016) Bing Xia et al. Immunotherapy
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
- (2016) Krista Dubin et al. Nature Communications
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors
- (2015) S. Lu et al. CLINICAL CANCER RESEARCH
- Nivolumab plus ipilimumab in the treatment of advanced melanoma
- (2015) Katy K. Tsai et al. Journal of Hematology & Oncology
- Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype
- (2015) Gang Xiao et al. Journal of Hematology & Oncology
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- (2015) M. Vetizou et al. SCIENCE
- Immunologic Checkpoints Blockade in Renal Cell, Prostate, and Urothelial Malignancies
- (2015) Sergio Bracarda et al. SEMINARS IN ONCOLOGY
- Mesenchymal Stromal Cells Prevent Allostimulation In Vivo and Control Checkpoints of Th1 Priming: Migration of Human DC to Lymph Nodes and NK Cell Activation
- (2015) C. Consentius et al. STEM CELLS
- Antibody targeting soluble NKG2D ligand sMIC refuels and invigorates the endogenous immune system to fight cancer
- (2015) Jennifer Wu OncoImmunology
- Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?
- (2014) Christian Rolfo et al. Expert Review of Anticancer Therapy
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients
- (2014) E. Cha et al. Science Translational Medicine
- Sustained Complete Response to CTLA-4 Blockade in a Patient with Metastatic, Castration-Resistant Prostate Cancer
- (2014) J. N. Graff et al. Cancer Immunology Research
- Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
- (2014) Lidia Robert et al. OncoImmunology
- Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
- (2013) Jedd D. Wolchok et al. Annals of the New York Academy of Sciences
- A selective role of NKG2D in inflammatory and autoimmune diseases
- (2013) Nadia Guerra et al. CLINICAL IMMUNOLOGY
- Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis
- (2013) Gang Liu et al. JOURNAL OF CLINICAL INVESTIGATION
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- NKG2D- and CD28-mediated costimulation regulate CD8+ T cell chemotaxis through different mechanisms: the role of Cdc42/N-WASp
- (2013) Esther Serrano-Pertierra et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
- (2013) Satoshi Wada et al. Journal of Translational Medicine
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
- (2013) M. J. Selby et al. Cancer Immunology Research
- Gut microbiota regulates NKG2D ligand expression on intestinal epithelial cells
- (2012) Camilla H. F. Hansen et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- NKG2D/Ligand dysregulation and functional alteration of innate immunity cell populations in pediatric IBD
- (2012) Raffaella La Scaleia et al. INFLAMMATORY BOWEL DISEASES
- IL-10 Suppression of NK/DC Crosstalk Leads to Poor Priming of MCMV-Specific CD4 T Cells and Prolonged MCMV Persistence
- (2012) Sanja Mandaric et al. PLoS Pathogens
- Activation of the Receptor NKG2D Leads to Production of Th17 Cytokines in CD4+ T Cells of Patients With Crohn's Disease
- (2011) Benjamin Pariente et al. GASTROENTEROLOGY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- NKG2D Initiates Caspase-Mediated CD3 Degradation and Lymphocyte Receptor Impairments Associated with Human Cancer and Autoimmune Disease
- (2010) N. Hanaoka et al. JOURNAL OF IMMUNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functional Dichotomy between NKG2D and CD28-Mediated Co-Stimulation in Human CD8+ T Cells
- (2010) Kamalakannan Rajasekaran et al. PLoS One
- Comprehensive assessment of T-cell receptor -chain diversity in T cells
- (2009) H. S. Robins et al. BLOOD
- Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells
- (2009) Hélène Bour-Jordan et al. IMMUNOLOGICAL REVIEWS
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
- (2009) Karl S. Peggs et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
- (2008) B. Kavanagh et al. BLOOD
- Soluble NKG2D ligands: prevalence, release, and functional impact
- (2008) Helmut Rainer Salih Frontiers in Bioscience-Landmark
- Tumor-derived soluble MICs impair CD3+CD56+ NKT-like cell cytotoxicity in cancer patients
- (2008) H WANG et al. IMMUNOLOGY LETTERS
- Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice
- (2008) A. Bai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
- Blockade of NKG2D signaling prevents the development of murine CD4+ T cell-mediated colitis
- (2007) Y. Ito et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started